tirzepatide in osa Diabetes & Weight Loss Drug Now Approved for (Obstructive Sleep Apnea) Terzapatid in Managing OSA
Description
For reference, the rate of discontinuation in the semaglutide study referenced above was 4.5% around half the rate of orforglipron with a longer trial period
Keeping a symptom diary for 57 days helps you and your PlexusDx provider identify patterns and distinguish tirzepatide effects from external triggers

PCOS affects approximately 10% of women during their reproductive years28

Four participants discontinued semaglutide because of adverse events

The clinical community closely observes the comparative data emerging from studies on retatrutide, tirzepatide, and semaglutide

Data may be made available through the corresponding author upon reasonable request and with permission of Carelon Research